Bioplastics producer Metabolix has survived the termination of its joint venture with DSM but is struggling to develop new sources of revenue. A shrinking cash reserve and the need to acquire financing for a new commercial-scale facility before substantial revenue growth can be achieved make a further decline in the company's share price likely. Only speculative investors with a high tolerance for risk should consider buying this company's shares.
Investors in bioplastics producer Metabolix (NASDAQ:MBLX) have experienced their fair share of volatility over the last year as the company's share price has made repeated 50% swings in both directions. Despite this volatility (or perhaps because of it), shares are trading at roughly the same level today...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|